Navigation Links
Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
Date:6/1/2009

CHICAGO, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented the results of a 5-aminosalicylic acid (5-ASA) persistency analysis entitled, "Twelve-month Persistence with 5-aminosalicylic Acid Therapy: Results from a Large Pharmacy Database," at Digestive Disease Week, on May 31, 2009. Results showed that after 12 months of therapy for continuing patients, 20 percent of Lialda patients were continually persistent, 9 percent of Asacol(R) (mesalamine) patients, 7 percent (250mg) and 10 percent (500mg) of Pentasa(R) (mesalamine) patients, 10 percent of balsalazide [combined results from generic balsalazide disodium and Colazal(R) (balsalazide disodium)] patients, and 10 percent (500mg) of Dipentum(R) (olsalazine sodium) patients were persistent. Continually persistent patients were defined as those who refilled their prescription within a period of up to twice the duration of the prescription that preceded the refill. Lialda is an FDA-approved, once-daily oral medication for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC). Safety and effectiveness of Lialda beyond eight weeks have not been established.

"Patients who have UC often face adherence challenges, and persistency is an important consideration in disease management," said Sunanda Kane, MD, MSPH, AGAF, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and lead investigator on database analysis. "We are pleased to have shared the results of the database analysis, which help us understand how many, and how often, patients are refilling their mesalamine prescriptions."

The database analysis evaluated the persistency of UC patients who filled a prescription for the aforementioned 5-
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... May 6, 2015 /CNW/ - Celebrities, bloggers and influencers across ... to spread the important message that melanoma prevention begins with ... Maria Sharapova , Hilary Duff , and parenting author ... out to their networks on Monday to share this poignant ... The David Cornfield Melanoma Fund (DCMF)-producers ...
(Date:5/6/2015)... May 6, 2015 CVS Health (NYSE: CVS ) ... Baltimore locations that sustained heavy fire damage during protests ... Baltimore over the past week or so, ... ahead," said CVS Health President and CEO Larry Merlo . ... to better health. There is no better way that we can ...
(Date:5/6/2015)... 06, 2015 Research and Markets ... the "Cannulas Market by Product (Nasal, Arterial, ... Microcannula), Material (Plastic, Metal) & End Users (Hospitals, ... report to their offering. The ... a CAGR of 5.6% from 2015 to 2020 ...
Breaking Medicine Technology:Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3
... Progress in Advancing Second-Generation ... CCR9 Drug towards ... announced the completion of enrollment of 436 patients in the,company,s ... a Phase II/III clinical trial of Traficet-EN(TM),(CCX282-B) in patients with ...
... DIEGO, June 12 Vical Incorporated,(Nasdaq: VICL ... of cash payments,and equity investments from AnGes MG, ... funding of the company,s ongoing,Allovectin-7(R) Phase 3 metastatic ... equity investments, Vical has received $15.3 million to ...
Cached Medicine Technology:ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4
(Date:5/7/2015)... NE (PRWEB) May 07, 2015 Aureus ... in travel nursing jobs and a variety ... health, has released an infographic spotlighting top theme ... infographic is aimed at thrill-seeking mobile healthcare professionals who ... , Travel healthcare careers offer an opportunity for the ...
(Date:5/7/2015)... and Washington, DC (PRWEB) May 07, 2015 ... Nebraska and Iowa -- CHI Health Bergan Mercy, ... in Omaha; CHI Health Midlands in Papillion, Neb.; ... -- have been recognized for achieving high-quality standards ... an independent, physician-led organization dedicated to best practices ...
(Date:5/6/2015)... Church, VA (PRWEB) May 07, 2015 ... Impact of NSF/IPEC/ANSI 363-2014, **FDAnews Webinar**, May 27, ... http://www.fdanews.com/NewGMPStandards , Most drugs contain 70-90% ... aids, binding agents or other purposes that facilitate ... globalization of the pharma industry, combined with a ...
(Date:5/6/2015)... 06, 2015 With an estimated 300,000 ... to its potentially dangerous health effects, the Horizon Foundation ... BEAM (Breathe Easier with Asthma Management) – to improve ... being funded through a $500,000 foundation grant to the ... is implementing BEAM throughout the state. , “While asthma ...
(Date:5/6/2015)... Edvance360 LMS-SN , a leader in ... Software & Information Industry Association's (SIIA) 30th annual ... Learning Management Solution" category. Edvance360 LMS-SN won the ... this award seven years running, continued proof that Edvance360 ... industry. , "The honor of being a CODiE ...
Breaking Medicine News(10 mins):Health News:Get to Know the Top Theme Parks: Aureus Medical Releases Infographic for the Travel Nurse and Other Travel Healthcare Professionals 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 2Health News:Five CHI Health Facilities in Nebraska, Iowa Recognized for High-Quality Care by Accreditation for Cardiovascular Excellence 3Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 2Health News:FDAnews Announces — New Standards for Excipient GMPs: Analyzing the Impact of NSF/IPEC/ANSI 363-2014 Webinar, May 27, 2015 3Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 2Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 3Health News:The Horizon Foundation for New Jersey and Boys & Girls Clubs in New Jersey Join Forces to Help Children with Asthma 4Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 2Health News:Edvance360 Wins 2015 CODiE Award for Best LMS, Winning Twice and Maintaining Finalist Status for Seven Years Running 3
... might even harm cognitive function , , MONDAY, May 12 (HealthDay ... that daily use of two popular pain-relieving drugs, Celebrex and ... family history of Alzheimer,s disease. , In fact, naproxen, which ... have a deleterious effect on cognitive function, the study found. ...
... Further Enhancing AnComm,s Ability To Help Texas Schools Stay ... ,Talk About It(R),-- the nation,s first and only anonymous ... pleased to announce the addition of,Catherine Toohey, M.Ed. to ... help Texas schools stay safe and avoid tragedies, Ms. ...
... reserved,for lighthearted fun and entertainment, the hallways of ... of gathering Monday, as child-health,and education experts and ... in Jordan. Her Majesty Queen Rania Al Abdullah ... there, bringing some,welcomed news about the Kingdom,s progress. ...
... Clinical Sciences performed the surgery that restored sight to 7-year-old ... Runnells. , "We are excited for Dixie," said Grozdanic. "She ... really worked. She was gradually going down visually and we ... quality of life." , "She is my pet and my ...
... Inc., a developer of advanced medical devices for ... that it has enrolled its,first patient in the ... U.S. registry study of the company,s OmniWave(TM) Endovascular,System ... limb ischemia (ALI). All patients enrolled in the ...
... serialization initiatives, CRANBURY, N.J., May 12 ... Systems (PES) for the pharmaceutical,industry, today announced ... central engineering and professional services,teams. The company ... to support,rapid worldwide deployments; specifically, the increasing ...
Cached Medicine News:Health News:Celebrex, Naproxen Won't Prevent Mental Decline 2Health News:Celebrex, Naproxen Won't Prevent Mental Decline 3Health News:AnComm's 'Talk About It(R)' Adds New School Safety Specialist 2Health News:Queen Rania Launches Situation Analysis of Children in Jordan Highlighting Jordan's Progress in Improving Quality of Life; 6 Ministers Commit to Further Improving Results 2Health News:Queen Rania Launches Situation Analysis of Children in Jordan Highlighting Jordan's Progress in Improving Quality of Life; 6 Ministers Commit to Further Improving Results 3Health News:Queen Rania Launches Situation Analysis of Children in Jordan Highlighting Jordan's Progress in Improving Quality of Life; 6 Ministers Commit to Further Improving Results 4Health News:ISU researcher performs first veterinary corneal implant procedure in US 2Health News:ISU researcher performs first veterinary corneal implant procedure in US 3Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Systech Augments Key Departments to Drive Operational Excellence and International Support 2Health News:Systech Augments Key Departments to Drive Operational Excellence and International Support 3
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistain SLS Linear Stainer is an economical mid-size linear stainer for staining procedures that do not require heat....
... a manual rotary microtome for routine paraffin ... designed to address repetitive stress injury. The ... tray, organizer storage tray and a resettable ... and may be disengaged at the user?s ...
... The Netmon remote monitoring service allows ... programmed and monitored from any location ... The service enhances preventive maintenance capabilities. ... access the unit (with your permission) ...
Medicine Products: